The authors present a method with the use of 99mTc-pyrophosphate for differential diagnosis of malignant and benign ovarian tumors. A total of 46 patients were examined. Of these, the sample hyperfixation in the zone of malignant ovarian tumors with the rate of differential accumulation of 200-260% was observed in 7. In benign tumors and inflammatory ovarian changes, radiopharmaceutical hyperfixation was either not observed or it did not exceed 130%. Diagnosis in all the patients was verified at operation with subsequent histological examination.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Diverse Roles of Long Non-Coding RNA HOTTIP in Breast and Gynecological Cancer Progression.
Curr Mol Med
January 2025
Department of Laboratory, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Long non-coding RNAs (lncRNAs) play vital roles in the development and progression of various tumors through multiple mechanisms. Among these, HOTTIP (HOXA transcript at the distal tip) stands out as an intriguing candidate with diverse functions in several malignancies, including breast cancer and gynecologic cancers such as ovarian, cervical, and endometrial cancers, which are significant global health concerns. HOTTIP interacts with key signaling pathways associated with these cancers, including Wnt/β-catenin, PI3K/AKT, and MEK/ERK pathways, enhancing their activation and downstream effects.
View Article and Find Full Text PDFMalignant Brenner Tumor of the Ovary: A Critical Reappraisal.
Int J Gynecol Pathol
November 2024
Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia.
Malignant Brenner tumors (MBTs) are rare epithelial tumors of the ovary, most likely arising from benign and borderline Brenner tumors. MBTs may be misdiagnosed as other primary carcinomas or nonepithelial tumors of the ovary as well as metastatic carcinomas. Accurate diagnosis usually requires clinical-radiologic correlation, extensive sampling, and immunohistochemical studies.
View Article and Find Full Text PDFBurden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
Cancer
January 2025
National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Background: Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female-specific cancers in China.
Methods: The year- and age-specific estimates of the incidence, mortality, and disability-adjusted life-years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study.
CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.
Mol Oncol
January 2025
Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
Forkhead box L2 (FOXL2) encodes a transcription factor essential for sex determination, and ovary development and maintenance. Mutations in this gene are implicated in syndromes involving premature ovarian failure and granulosa cell tumors (GCTs). This rare cancer accounts for less than 5% of diagnosed ovarian cancers and is causally associated with the FOXL2 c.
View Article and Find Full Text PDFIdentification of the novel BRCA1 c.2463_2464delTA mutation in two high grade serous ovarian cancer sisters and potential dosage effects implications: a case report.
Mol Biol Rep
January 2025
Department of Clinical Pathology, San Giovanni Addolorata Hospital, Rome, Italy.
Background: Ovarian Cancer is one of the leading causes of cancer death among women worldwide and the therapeutic landscape to treat it is constantly evolving. One of the major points of decision for the treatment choice is the presence of some genomic alterations that could confer sensitivity to the new available therapies including inhibitors of poly (ADP-ribose) polymerase (PARPi) with BRCA1 and 2 genes playing the most important role.
Methods And Results: We performed the search for any somatic and/or germline alteration in patient's samples by next generation sequencing (NGS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!